{"id":4352,"date":"2023-06-16T10:30:41","date_gmt":"2023-06-16T10:30:41","guid":{"rendered":"http:\/\/fda.no\/?page_id=4352"},"modified":"2025-06-05T11:58:46","modified_gmt":"2025-06-05T11:58:46","slug":"aktsomhetsvurderinger-etter-apenhetsloven","status":"publish","type":"page","link":"https:\/\/fda.no\/is\/aktsomhetsvurderinger-etter-apenhetsloven\/","title":{"rendered":"\u00c1rei\u00f0anleikak\u00f6nnun samkv\u00e6mt l\u00f6gum um hreinskilni"},"content":{"rendered":"<p>Yfirl\u00fdsing um \u00e1rei\u00f0anleikakannanir samkv\u00e6mt l\u00f6gum um hreinskilni<\/p>\n\n\n\n<p class=\"translation-block\">Til a\u00f0 takast \u00e1 vi\u00f0 raunverulegar og hugsanlegar neikv\u00e6\u00f0ar aflei\u00f0ingar fyrir grundvallarmannr\u00e9ttindi og manns\u00e6mandi vinnua\u00f0st\u00e6\u00f0ur hefur fyrirt\u00e6ki\u00f0 \u00e1\u00f0ur sett s\u00e9r verklagsreglur um tilkynningar, kvartanir og \u00e1takastj\u00f3rnun. A\u00f0 auki h\u00f6fum vi\u00f0 komi\u00f0 \u00e1 verklagi um \u00e1framhaldandi mat \u00e1 birgjum \u00feannig a\u00f0 fr\u00e1 og me\u00f0 2023 ver\u00f0a n\u00fdir birgjar a\u00f0 svara k\u00f6nnun okkar \u00e1\u00f0ur en \u00feeir eru metnir sem birgir. Einnig hafa veri\u00f0 sam\u00feykktar <a href=\"http:\/\/fda.no\/is\/code-of-conduct\/\" target=\"_blank\" rel=\"noopener\" title=\"\">si\u00f0areglur<\/a> sem l\u00fdsa si\u00f0areglur f\u00e9lagsins, auk verklags sem l\u00fdsir vinnua\u00f0fer\u00f0um vi\u00f0 \u00e1rei\u00f0anleikak\u00f6nnun.<\/p>\n\n\n\n<p>FDA AS har i 2024 gjennomf\u00f8rt aktsomhetsvurderinger ved \u00e5;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>rette en sp\u00f8rreunders\u00f8kelse til v\u00e5re leverand\u00f8rer. Unders\u00f8kelsen ble sendt ut noe senere enn tidligere \u00e5r, og det er derfor et mindretalls bedrifter som hittil har besvart unders\u00f8kelsen. <\/li>\n\n\n\n<li>I etterkant skal administrasjon og daglig leder utf\u00f8re risikovurderinger basert p\u00e5 svar fra unders\u00f8kelsen.<\/li>\n\n\n\n<li>I tillegg vil det bli gjort vurderinger basert p\u00e5 v\u00e5r kjennskap til alle v\u00e5re leverand\u00f8rer.<\/li>\n<\/ul>\n\n\n\n<p>Vi\u00f0 h\u00f6fum einnig lagt mat \u00e1 eigin rekstur me\u00f0 \u00e1herslu \u00e1 allar n\u00faverandi og hugsanlegar neikv\u00e6\u00f0ar aflei\u00f0ingar af starfsemi f\u00e9lagsins. \u00c1 grundvelli m\u00e1lefnamats h\u00f6fum vi\u00f0 ekki s\u00e9\u00f0 \u00fe\u00f6rf \u00e1 \u00f3venjulegum r\u00e1\u00f0st\u00f6funum a\u00f0 \u00f6\u00f0ru leyti en \u00fev\u00ed a\u00f0 vi\u00f0 munum tilgreina b\u00e6\u00f0i fyrir n\u00fdja og n\u00faverandi birgja a\u00f0 \u00feeir ver\u00f0i a\u00f0 svara birgjak\u00f6nnun\/fyrirspurnum okkar var\u00f0andi \u00e1rei\u00f0anleikak\u00f6nnun til a\u00f0 geta veri\u00f0 metnir sem birgir.<\/p>\n\n\n\n<p>Jafnframt munum vi\u00f0 halda \u00e1fram st\u00f6\u00f0ugum umb\u00f3tum \u00ed starfsemi okkar og me\u00f0 \u00fev\u00ed a\u00f0 fylgja og \u00fer\u00f3a \u00e1fram lei\u00f0beiningar okkar og verklag \u00ed g\u00e6\u00f0akerfinu, halda \u00e1fram a\u00f0 einbeita okkur a\u00f0 tilgangi gagns\u00e6islaganna. <\/p>","protected":false},"excerpt":{"rendered":"<p>Redegj\u00f8relse for aktsomhetsvurderinger etter \u00c5penhetsloven For \u00e5 h\u00e5ndtere faktiske og potensielle negative konsekvenser for grunnleggende menneskerettigheter og anstendige arbeidsforhold har selskapet tidligere etablert prosedyre for varsling, klager og konflikth\u00e5ndtering. I tillegg har vi etablert en prosedyre for l\u00f8pende leverand\u00f8revaluering slik at fra 2023 m\u00e5 nye leverand\u00f8rer besvare v\u00e5r sp\u00f8rreunders\u00f8kelse f\u00f8r de blir vurdert som leverand\u00f8r. &#8230; <a title=\"\u00c1rei\u00f0anleikak\u00f6nnun samkv\u00e6mt l\u00f6gum um hreinskilni\" class=\"read-more\" href=\"https:\/\/fda.no\/is\/aktsomhetsvurderinger-etter-apenhetsloven\/\" aria-label=\"Read more about Aktsomhetsvurderinger etter \u00c5penhetsloven\">Read more<\/a><\/p>","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-4352","page","type-page","status-publish"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/fda.no\/is\/wp-json\/wp\/v2\/pages\/4352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fda.no\/is\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/fda.no\/is\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/fda.no\/is\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fda.no\/is\/wp-json\/wp\/v2\/comments?post=4352"}],"version-history":[{"count":4,"href":"https:\/\/fda.no\/is\/wp-json\/wp\/v2\/pages\/4352\/revisions"}],"predecessor-version":[{"id":5064,"href":"https:\/\/fda.no\/is\/wp-json\/wp\/v2\/pages\/4352\/revisions\/5064"}],"wp:attachment":[{"href":"https:\/\/fda.no\/is\/wp-json\/wp\/v2\/media?parent=4352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}